Hydrogen Gas Helps Heart Problems in Kawasaki Disease Study
- Authors
- Wen-Ling Shih, Tsung-Ming Yeh, Kuang-Den Chen, Steve Leu, Shih-Feng Liu, Ying-Hsien Huang, Ho-Chang Kuo
- Journal
- Life
- Year
- 2024
- DOI
- 10.3390/life14070796
- Study Type
- Mouse
- Outcome
- Positive
- Peer Reviewed
- Yes
- Country
- Taiwan
- Health Condition
- Kawasaki Disease
- Body System
- Cardiovascular
TL;DR
Inhaling hydrogen gas reduced heart artery swelling and inflammation in mice with a disease similar to Kawasaki disease in children.
Key Finding
Inhaled hydrogen gas significantly reduced coronary artery dilatation and decreased inflammatory markers (IL-6) in a mouse model of Kawasaki disease.
Summary
Kawasaki disease is a serious condition in young children that causes inflammation of blood vessels, particularly in the heart's coronary arteries. This study tested whether breathing hydrogen gas could help treat coronary artery damage in mice engineered to have Kawasaki disease. Researchers found that hydrogen gas inhalation reduced the abnormal widening of coronary arteries and lowered inflammatory markers (IL-6) in treated mice compared to untreated mice.
Practical Takeaway
This is early-stage research in mice only, so it does not yet show whether hydrogen gas would work in children with Kawasaki disease. The findings suggest hydrogen's antioxidant properties may help reduce inflammation and vessel damage, but human clinical trials would be needed to determine if this approach is safe and effective for actual patients.
Abstract
Background: Kawasaki disease (KD) is a syndrome primarily affecting young children, typically under the age of five, and is characterized by the development of acute vasculitis. Through extensive research conducted on both murine and human subjects, it has been demonstrated that heightened levels of reactive oxygen species (ROS) play a pivotal role in the development of KD, especial coronary artery lesions (CALs). Hydrogen gas exhibits potent antioxidant properties that effectively regulate ROS production and the inflammatory response. Methods: We used Lactobacillus casei cell wall extract (LCWE)-induced vasculitis in mice as an animal model of KD and treated the mice with hydrogen gas inhalation. Results: We observed significant dilatation and higher Z scores in the left coronary artery (LCA) in D21 and D28 in mice after LCWE treatment compared to the control group (p < 0.001) and a significant resolution of LCA diameters (p < 0.01) and Z scores (p < 0.01) after treatment with inhaled hydrogen gas. We further demonstrated that serum IL-6 expression was higher in mice after LCWE treatment (p < 0.01) and IL-6 significantly decreased after inhaled hydrogen gas therapy (p < 0.001). Conclusion: According to our literature review, this is the first report where hydrogen gas inhalation has been demonstrated to be effective for the treatment of coronary artery dilatation in a KD murine model.